-
Dr. Jie Jin: the New JAK Inhibitor Jaktinib in the Treatment of Myelofibrosis (MF)
The 28th European Hematology Association (EHA) Congress was held from June 8th to June 11th, 2023, in Frankfurt, Germany, in a hybrid format combining online and offline meetings. As the largest international conference in the field of European hematology, the EHA Congress covered a wide range of scientific topics, clinical and basic research, including both…
-
The Mysteries of Hepatitis D: Key Molecular Determinants in Virus Replication and Assembly
Dr. Wenshi Wang is the Principal Investigator of the hepatitis virus research group, Xuzhou Medical University, China. He obtained his Ph.D. from Erasmus University Rotterdam, the Netherlands, and completed post-doc research training at Heidelberg University, Germany in the field of hepatitis viruses. He has contributed more than 50 peer-reviewed publications, with 20 first or corresponding…
-
ESMO 2023 | Professor Feng Jin: Less is More – New Evidence Added to Surgery Exemption After Neoadjuvant Therapy for Breast Cancer
Editor’s Note: The European Society for Medical Oncology (ESMO), as a globally renowned academic conference in the field of oncology, announces numerous cutting-edge developments each year. The ESMO 2023 annual…
-
ESMO Hot Topic: Success Imminent in MATTERHORN Phase III Study, Neoadjuvant Durvalumab Shows Promising Progress for Gastric Cancer pCR
Editor’s Note: The 2023 ESMO Annual Meeting took place from October 20th to 24th in Madrid, Spain. As a highly authoritative annual event in the field of oncology, it unveils…
-
AASLD Voice of China | Dr. Hongfei Zhang’s Team: Latest Stage Data Revealed for China’s “Sprout” Project, Aiding Clinical Cure for Children with Chronic Hepatitis B
Editor’s Note: Chronic hepatitis B is the leading cause of liver disease in Chinese children, posing a serious threat to their health. The “Sprout” project is China’s first large-scale real-world…
-
AASLD Voice of China | Dr. Chao Wu and Dr. Jie Li’s Team at Nanjing Drum Tower Hospital Focus on Non-invasive Diagnosis
Risk Factors, and Treatment Management of Hepatitis, Yielding Fruitful Results! Editor’s Note: Hepatitis B virus (HBV) infection is a widespread global health issue. According to the World Health Organization, as…
-
New KRAS G12C Inhibitor Shows Early Efficacy in Solid Tumors and Previously Treated NSCLC
According to results from the phase 1a/1b LOXO-RAS-20001 study (NCT04956640) showcased at the 2023 American Association for Cancer Research (AACR) annual meeting, the KRAS G12C inhibitor LY3537982 exhibited clinical efficacy in patients with non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and other solid tumors. This is a phase I study of LY3537982 treating locally…
-
Emerging Lymphoma Therapies at AACR 2023: Promising Results in CD19 Immunotherapy, CAR-T Cells, and Dual-Specific Antibodies
The 2023 American Association for Cancer Research (AACR) Annual Meeting was held in Orlando, USA, from April 14 to 19, 2023. Every year, the AACR Congress reports numerous clinical, basic, and translational studies on cancer, especially innovative therapies in the preliminary phase I/II research stages. At this year’s AACR conference, three clinical trials were reported…
Connecting Medical Expertise through Media